2022
Chapter 23 Polycystic ovarian syndrome and reproductive failure
Duero J, Tal R. Chapter 23 Polycystic ovarian syndrome and reproductive failure. 2022, 351-378. DOI: 10.1016/b978-0-323-90805-4.00009-2.ChaptersPolycystic ovarian syndromeInsulin resistanceOvarian syndromeEndometrial receptivityUterine abnormalitiesReproductive dysfunctionPathophysiology of PCOSRecurrent pregnancy lossReproductive-age womenAbnormal follicular developmentRisk of obesityComplex endocrine disorderEndometrial gene expressionMajority of womenType II diabetesPregnancy complicationsPolycystic ovariesPreterm birthPlacental dysfunctionChronic inflammationClinical manifestationsEndocrine disordersImplantation failurePregnancy lossCardiovascular disease
2015
Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial
Irani M, Seifer DB, Grazi RV, Julka N, Bhatt D, Kalgi B, Irani S, Tal O, Lambert-Messerlian G, Tal R. Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 4307-4314. PMID: 26485217, DOI: 10.1210/jc.2015-2580.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CDBiological AvailabilityCholecalciferolDehydroepiandrosterone SulfateEndoglinFemaleHumansInsulin ResistanceLipidsPolycystic Ovary SyndromeProspective StudiesReceptors, Cell SurfaceSocioeconomic FactorsTestosteroneTransforming Growth Factor beta1Vitamin DVitamin D DeficiencyVitaminsYoung AdultConceptsPolycystic ovary syndromeVD supplementationTGF-β1Clinical manifestationsClinical parametersAcademic-affiliated medical centerFerriman-Gallwey scoreOral vitamin D3Serum TGF-β1Soluble endoglin levelsPlacebo-controlled trialVitamin D supplementationTGF-β1 levelsNew treatment modalitiesD supplementationOral placeboRandomized PlaceboOvary syndromeVD levelsEndoglin levelsInsulin resistanceTreatment modalitiesMenstrual periodLipid profileVitamin D3